Eli Lilly | Passifs Courants



Current Liabilities Changement Date
AbbVie USD 38.75B 4.31B 2024-12
Abbott USD 14.16B 745M 2024-12
ALKERMES USD 465.2M 11.5M 2024-12
Amgen USD 23.1B 2.79B 2024-12
AstraZeneca USD 27.87B 1.94B 2024-12
Baxter International USD 6.51B 311M 2024-12
Biogen USD 5.53B 103.8M 2024-12
Bristol-Myers Squibb USD 23.77B 1.14B 2024-12
Drreddys Laboratories INR 131.95B 2.65B 2024-12
Eli Lilly USD 28.38B 3.7B 2024-12
Gilead Sciences USD 12B 279M 2024-12
GlaxoSmithKline GBP 21.7B 238M 2024-12
Glaxosmithkline GBP 21.7B 238M 2024-12
Indivior 962M 50M 2024-09
J&J USD 50.32B 1.44B 2024-12
Medtronic USD 11.84B 355M 2025-01
Merck USD 28.42B 1.17B 2024-12
Neurocrine Biosciences USD 507.7M 78M 2024-12
Novartis USD 28.69B 560M 2024-12
Novartis USD 28.69B 560M 2024-12
Novo Nordisk 208.36B 20.45B 2024-09
Perrigo USD 1.04B 406.3M 2024-12
Pfizer USD 43B 216M 2024-12
Prestige Brands USD 102.54M 4.36M 2024-12
Regeneron Pharmaceuticals USD 5.7B 2.04B 2024-12
Roche Holding CHF 27.02B 424M 2024-12
Sanofi 30.03B 5.82B 2024-06
Sanofi 30.03B 5.82B 2024-06
United Therapeutics USD 738.1M 135.3M 2024-12
Zoetis USD 3.41B 1.71B 2024-12



Eli Lilly Passifs Courants - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2025.